Comprehensive, actionable carrier screening
Horizon carrier screening helps couples determine the risk of passing on serious genetic conditions to their child. It can be performed either preconception (ideally) or during pregnancy.
Carriers are common, and family history is not a predictor
Family history: not a predictor
88% of carriers of cystic fibrosis (CF), spinal muscular atrophy (SMA), and fragile X syndrome have no known family history1
1 in 9 people are carriers when screened with the Horizon 14 standard panel2
1 in 634 babies born are affected by one of the conditions in the Horizon 14 standard panel2
The American College of Obstetricians and Gynecologists (ACOG) says…
Carrier screening is no longer a “nice-to-have”; it’s now best practice — regardless of ethnicity and screening strategy. ACOG recommends carrier screening for all patients either preconception or during pregnancy.3
The American College of Obstetricians and Gynecologists (ACOG)
Carrier screening facilitates informed decision-making and early preparation
- Get genetic counseling
- Pursue alternative reproductive options
- Undergo diagnostic testing
- Assemble an appropriate care team and specialist facility for delivery
- Plan financially and prepare emotionally
- Access early interventions including FDA-approved treatment and clinical trials
Leading-edge technology meets support for your patients and practice
Horizon carrier screening leverages next-generation sequencing technology to give your patients comprehensive insights on their risk of passing on serious genetic conditions. Horizon uniquely combines actionable results with support resources tailored for your patients and practice.
High detection rates — advanced technology detects more carriers
Traditional genotyping tests can miss up to 44% of carriers detected by Horizon.2
ACOG says….“A number of expanded mutation panels…can be considered to enhance sensitivity for carrier detection, especially in non-Caucasian ethnic groups.”4
Spinal muscular atrophy
Traditional screening misses ~60% of patients Horizon identifies as at risk.2
ACOG says…“[A subset] of the general population…will not be identified as being a carrier…”4
CBC (complete blood count) and electrophoresis testing alone could miss 90% of alpha- and 6% of beta-hemoglobinopathy carriers detected by Horizon.2
ACOG says…“A combination of laboratory tests may be required to provide the information necessary to counsel couples…”4
Comprehensive support — tools and services meeting provider and patient needs
Horizon / Panorama Combo Kit requires only one blood draw, requisition form, and kit.
The Patient Call-Out Program (PCOP) delivers results and provides interactive genetic education via NEVA (Natera’s Educational Virtual Assistant), available 24/7.
Partner Auto-Enroll streamlines your workflow for testing partners of patients with positive Horizon results.
1Archibald, A., Smith, M., Burgess, T. et al. Genet Med 20, 513–523 (2018). https://doi.org/10.1038/gim.2017.134
2Westemeyer, M., Saucier, J., Wallace, J. et al. Genet Med (2020). https://doi.org/10.1038/s41436-020-0807-43.
3American College of Obstetricians and Gynecologists, Committee Opinion #690, March 2017.
4American College of Obstetricians and Gynecologists, Committee Opinion #691, March 2017.